Effectiveness of SMS 201-995, a synthetic, long-acting somatostatin analogue, in treatment of quinine-induced hyperinsulinaemia.
SMS 201-995, a new long-acting, synthetic somatostatin analogue, dose 50 micrograms/h, given as a continuous intravenous infusion, completely abolished quinine-induced insulin release in 9 healthy Thai volunteers. Hyperinsulinaemia, which caused sustained hypoglycaemia in a 32-year-old post-partum Thai patient who was receiving intravenous quinine for falciparum malaria, was suppressed within 30 min of starting SMS 201-995, and the patient became fully conscious. This octapeptide antagonises the stimulatory effect of quinine on the pancreatic beta cell and is a specific therapy for life-threatening hyperinsulinaemic hypoglycaemia complicating falciparum malaria.
Phillips
R E
RE
Warrell
D A
DA
Looareesuwan
S
S
Turner
R C
RC
Bloom
S R
SR
Quantrill
D
D
Moore
A R
AR
D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D003864:Depression, Chemical; D004341:Drug Evaluation; D005260:Female; D005934:Glucagon / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007263:Infusions, Parenteral; D007328:Insulin / Q000097:blood*; D008288:Malaria / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D015282:Octreotide; D010963:Plasmodium falciparum; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy; D011803:Quinine / Q000009:adverse effects*; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D001786:Blood Glucose; D007328:Insulin; D013004:Somatostatin; D005934:Glucagon; D011803:Quinine; D015282:Octreotide